Structure Therapeutics to Release ACCESS Clinical Data for Aleniglipron on December 8, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 hour ago0mins
- Clinical Data Release: Structure Therapeutics plans to release topline data from the ACCESS clinical program for aleniglipron before market opens on December 8, 2025, which is expected to provide crucial clinical evidence for the company's innovative obesity treatment.
- Management Call: The management team will host a conference call and webcast at 8:30 AM ET on the same day to discuss the clinical data, which will not only enhance investor confidence but also lay the groundwork for future financing and market promotion.
- Technological Platform Advantage: Utilizing its next-generation structure-based drug discovery platform, Structure Therapeutics is developing oral small molecule therapies for obesity, aiming to overcome scalability limitations of traditional biologics and peptide therapies, thereby benefiting more patients worldwide.
- Market Potential: With the global obesity crisis worsening, the successful launch of aleniglipron will help meet significant unmet medical needs, further solidifying the company's market position in the biopharmaceutical industry.
GPCR.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on GPCR
Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 73.38 USD with a low forecast of 50.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.850
Low
50.00
Averages
73.38
High
100.00
Current: 32.850
Low
50.00
Averages
73.38
High
100.00
Citi
Buy
maintain
$60
2025-11-03
Reason
Citi
Price Target
$60
2025-11-03
maintain
Buy
Reason
Citi opened a "positive 90-day catalyst watch" on shares of Structure Therapeutics while keeping a Buy rating on the name with a $60 price target. Citi views Structure's risk/reward into the Phase 2b ACCESS and ACCESS II data for aleniglipron, expected by the end of 2025, as favorable.
Citizens JMP
NULL -> Outperform
maintain
$89 -> $87
2025-08-07
Reason
Citizens JMP
Price Target
$89 -> $87
2025-08-07
maintain
NULL -> Outperform
Reason
Citizens JMP lowered the firm's price target on Structure Therapeutics to $87 from $89 and keeps an Outperform rating on the shares following the Q2 report. The firm says the company will release the Phase 2b data for aleniglipron by the end of 2025.
Leerink
David Risinger
Outperform
to
NULL
downgrade
$60 -> $44
2025-08-07
Reason
Leerink
David Risinger
Price Target
$60 -> $44
2025-08-07
downgrade
Outperform
to
NULL
Reason
Leerink analyst David Risinger lowered the firm's price target on Structure Therapeutics to $44 from $60 and keeps an Outperform rating on the shares. The firm cites change to its terminal growth rate to reflect longer-term competition. Leerink notes that Structure reiterated that it continues to anticipate topline Phase 2b 36-week data from oral small molecule GLP-1 aleniglipron ACCESS and ACCESS II studies by year-end 2025. The company is also expanding aleniglipron's clinical development program to optimize competitive positioning and its future Phase 3 program.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$60 -> $75
2025-08-07
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$60 -> $75
2025-08-07
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Structure Therapeutics (GPCR) to $75 from $60 and keeps a Buy rating on the shares. The firm views Eli Lilly's (LLY) orforglipron data from the ATTAIN-1 study showing 12.4% body weight loss from the baseline as "encouraging" for Structure's aleniglipron. Given Lilly's data, aleniglipron "may emerge as a strong contender for best-in-class profile based on several differentiating factors," the analyst tells investors in a research note.
See All Ratings
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?